XML 42 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:      
Net loss $ (190,228) $ (105,385) $ (52,248)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 5,870 3,775 1,019
Stock-based compensation 30,522 16,281 6,925
Amortization of premiums and accretion of discounts on marketable securities 584 (4,701) (2,745)
Amortization of right-of-use assets 1,395 1,799  
Impairment loss on right-of-use assets 238 1,158  
Loss from disposal of property and equipment, net 107 39 151
Changes in operating assets and liabilities:      
Prepaid expenses and other current assets (3,839) (1,596) (2,245)
Other assets (2,498) (42) 106
Accounts payable 2,409 152 (809)
Accrued liabilities and accrued clinical supply costs 12,232 9,210 4,743
Deferred revenue (21,098) (21,219) 172,492
Lease liabilities (2,407) 868  
Other long-term liabilities (21) 353 75
Net cash provided by (used in) operating activities (166,734) (99,308) 127,464
Cash flows from investing activities:      
Purchase of property and equipment (5,032) (15,265) (1,884)
Purchase of marketable securities (506,809) (529,609) (472,235)
Maturities of marketable securities 406,790 496,000 250,000
Net cash used in investing activities (105,051) (48,874) (224,119)
Cash flows from financing activities:      
Proceeds from issuance of common stock upon initial public offering, net of issuance costs   170,128 (1,904)
Proceeds from issuance of common stock upon follow-on public offering, net of issuance cost 224,603 (92)  
Proceeds from issuance of convertible preferred stock, net of issuance costs     133,050
Proceeds from the exercise of options to purchase common stock 6,331 1,519  
Proceeds from issuance of stock from employee stock purchase plan 1,179 798  
Net cash provided by financing activities 232,113 172,353 131,146
Net increase (decrease) in cash, cash equivalents, and restricted cash (39,672) 24,171 34,491
Cash, cash equivalents, and restricted cash at beginning of period 91,113 66,942 32,451
Cash, cash equivalents, and restricted cash at end of period 51,441 91,113 66,942
Non-cash investing and financing activities:      
Property and equipment purchases included in accounts payable and accrued liabilities $ 428 3,471 293
Deferred offering costs in accrued liabilities   465 792
Tenant improvements paid by landlord   $ 8,286 $ 7,449